Free Publications

Search for cll returned 189 results

Glossary Results

Relapsed CLL

CLL that responded to treatment but then returns.

Refractory CLL

CLL that has not responded to initial treatment. Refractory disease may be disease that is getting worse or staying the same (stable disease).

CD38

An antigen on CLL cells and other cells. The expression of CD38 may be a marker to assist in predicting CLL progression.

Richter transformation

In a small number of patients, there is a progression in their disease. In these patients, CLL takes on the characteristics of an aggressive lymphoma. This change is not a second cancer, but a transformation of the CLL cells.

Small lymphocytic lymphoma (SLL)

A disease with symptoms and treatment that are much like CLL. SLL starts in a lymphocyte in a lymph node. CLL starts in a lymphocyte in the marrow.

Immunoglobulin Heavy Chain Variable Region (IgHv) Gene Status

A marker that can distinguish between CLL subtypes (unmutated IgHv and mutated IgHv). People with CLL with unmutated IgHv gene status may have a more progressive form of the disease.

Zap-70

An abbreviation for the cell protein “zeta-associated protein 70.” A high level of ZAP-70 expression on the cells of patients with B-cell CLL is one of several factors that may predict more progressive disease. Outside of a research laboratory this test is generally not very reliable and should not be used.

Chronic Lymphocytic Leukemia (CLL)

Over the past 10 years, The Leukemia & Lymphoma Society (LLS) has invested more than $52 million to accelerate pioneering research in chronic lymphocytic leukemia (CLL), a blood cancer characterized by the development of too many white blood cells called lymphocytes. Our investment has unlocked new insights on CLL disease mechanisms and advanced new therapies to improve outcomes and care for patients.. Despite its name, Chronic Lymphocytic Leukemia is actually a type of non-Hodgkin ...

  • Photo
Read more

Evolutionary Behavior in CLL: Implications for Personalized Therapy

Erik Nelson and Anne-Marie Silvi​
May 15, 2019

In recent years, there has been a rapid surge in the amount of genomic information available to researchers. This information enhances the understanding of human disease and provides the fuel needed to achieve personalized medicine. New advances in technology and in the ability to analyze massive datasets have allowed scientists to more precisely define cancer behavior, including how these diseases adapt to evade therapy. ...

  • Photo
Read more

What is CLL?

Let’s talk about white blood cells. White blood cells are part of the body’s immune system. Lymphocytes are a type of white blood cell. These cells are made in the bone marrow as well as in the blood and lymph tissue. There are different types of lymphocytes that have specific roles; however, they all perform special tasks that help defend our bodies against bacteria, fungal or viral infections. Chronic Lymphocytic Leukemia (also called CLL) is a type of blood cancer that results fro ...

Read more

Chronic Lymphocytic Leukemia (CLL): Diagnosis, Treatment and Side Effects Management

Recorded on March 30, 2020

Click Here to Participate Format: Recorded Webinar
CE Credits available until: May 15, 2021
  Target Audience Nurse practitioners, nurses and oncology social workers involved in the care of patients with chronic lymphocytic leukemia (CLL) Course Content Level for Social Workers: Intermediate and Advanced       
  Description This webinar will provide a basic o ...

  • Photo
Read more

Fact or Fiction? CLL Treatment and Side Effects

Presented by Patient Empowerment Network   September 17, 2019

Video will be available soon.
  Topics Covered When searching for chronic lymphocytic leukemia (CLL) information online, how do you know what’s credible? In this webinar, Dr. Javier Pinilla-Ibarz, will review current CLL treatments, emerging research and common side effects to help you decipher fact from fiction.   Speaker Javier Pinilla-Ibarz, MD, PhD
Lymphoma ...

  • Photo
Read more

Pages

Glossary Results

Relapsed CLL

CLL that responded to treatment but then returns.

Refractory CLL

CLL that has not responded to initial treatment. Refractory disease may be disease that is getting worse or staying the same (stable disease).

CD38

An antigen on CLL cells and other cells. The expression of CD38 may be a marker to assist in predicting CLL progression.

Richter transformation

In a small number of patients, there is a progression in their disease. In these patients, CLL takes on the characteristics of an aggressive lymphoma. This change is not a second cancer, but a transformation of the CLL cells.

Small lymphocytic lymphoma (SLL)

A disease with symptoms and treatment that are much like CLL. SLL starts in a lymphocyte in a lymph node. CLL starts in a lymphocyte in the marrow.

Immunoglobulin Heavy Chain Variable Region (IgHv) Gene Status

A marker that can distinguish between CLL subtypes (unmutated IgHv and mutated IgHv). People with CLL with unmutated IgHv gene status may have a more progressive form of the disease.

Zap-70

An abbreviation for the cell protein “zeta-associated protein 70.” A high level of ZAP-70 expression on the cells of patients with B-cell CLL is one of several factors that may predict more progressive disease. Outside of a research laboratory this test is generally not very reliable and should not be used.